Sintilimab

Bispecific antibody drug conjugates (BsADCs) market poised for growth, with China leading in clinical trials and first commercial approval expected by 2029. Key players include Alhamab Oncology and Sichuan Baili Pharmaceutical, with BsADCs targeting breast cancer and solid tumors. Regulatory agencies are increasingly approving BsADC candidates for clinical trials, and collaborations are accelerating development.

Innovent Biologics' earnings report shows revenue up 46% to 3.95 billion yuan, but net loss surges 182% to 393 million yuan. The delay in sales approval for anti-obesity drug mazdutide and the sudden retirement of R&D chief Liu Yongjun dampen investor enthusiasm. Innovent's focus shifts to cardiovascular and metabolic drugs, with mazdutide and teprotumumab in the pipeline.

Innovent Biologics to present nearly 20 clinical data on novel oncology molecules at WCLC and ESMO, including updated Phase 1 results of IBI363 in NSCLC and colorectal cancer, pivotal Phase 2 results of Dupert in NSCLC, and Phase 1 results of IBI354 in HER2+ solid tumors.